Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

NCT06694636 | Recruiting

• 1 other identifier: 2024ZDSYLL167-P01
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma; Sympathetic Nerves; Intravascular Radiofrequency Ablation

Outcome Measures

Primary Outcomes (1)

• ORR

  Objective Response Rate

  every month, up to 1 year

Secondary Outcomes (2)

• PFS

  every month, up to 1 year

• DCR

  every month, up to 1 year

Study Arms (1)

Intravascular Radiofrequency Ablation of Sympathetic Nerves Group

EXPERIMENTAL

Enrolled patients will receive Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

Procedure: endovascular radiofrequency ablation and desympathetic nerve surgery

Interventions

endovascular radiofrequency ablation and desympathetic nerve surgery PROCEDURE

endovascular radiofrequency ablation and desympathetic nerve surgery

Intravascular Radiofrequency Ablation of Sympathetic Nerves Group

Eligibility Criteria

• Age: 25 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
• Locally progressed or distant metastatic unresectable advanced HCC
• Progressed after second-line therapy
• Agree to participate in the study and sign the informed consent form

You may not qualify if:

• Not suitable for ablation surgery
• Pregnant, lactating and planning to become pregnant
• Orthostatic hypotension
• Mixed liver cancer
• Intestinal obstruction
• Obvious bleeding tendencies and hematologic diseases
• Acute or severe systemic infection;
• Stroke or transient ischemic attack (TIA) within two weeks;
• Acute coronary syndrome within two weeks;
• Evaluated to be not suitable for this trial by investigators

Sponsors & Collaborators

• Zhongda Hospital: lead

Study Sites (1)

Zhongda Hospital

Nanjing, Jiangsu, 210009, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Gao-Jun Gao-Jun

  Zhongda Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hai-Dong Zhu

CONTACT

+86-25-83272121; zhuhaidong9509@163.com

Teng

CONTACT

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Interventional and Vascular Surgery Department

Model Details: Enrolled patients will receive intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

Study Record Dates

• First Submitted: July 24, 2024
• First Posted: November 19, 2024
• Study Start: February 1, 2024
• Primary Completion: February 1, 2026
• Study Completion: February 1, 2026
• Last Updated: November 19, 2024

Record last verified: 2024-11

Locations

CN (1)